• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于研究蛋氨酸限制引发代谢的临床前乳腺癌模型

Preclinical Breast Cancer Models to Investigate Metabolic Priming by Methionine Restriction.

作者信息

Strekalova Elena, Malin Dmitry, Rajanala Harisha, Cryns Vincent L

机构信息

Department of Medicine, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

出版信息

Methods Mol Biol. 2019;1866:61-73. doi: 10.1007/978-1-4939-8796-2_6.

DOI:10.1007/978-1-4939-8796-2_6
PMID:30725408
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6571148/
Abstract

We have developed a novel therapeutic paradigm ("metabolic priming") for cancer whereby restriction of the essential amino acid methionine activates a number of cell-stress-response pathways that can be selectively targeted to enhance the therapeutic impact of methionine restriction. One example of metabolic priming is the combination of methionine restriction with proapoptotic TRAIL receptor-2 (TRAIL-R2) agonists. Methionine restriction enhances the cell surface expression of TRAIL-R2 selectively in transformed breast epithelial cells and renders them more susceptible to cell death induction by TRAIL-R2 agonists in cellular and murine models of breast cancer. This methods review focuses on preclinical models of breast cancer to investigate metabolic priming by methionine restriction. Multiple cell-based methods are detailed to measure cell viability, cell survival, caspase activity, apoptosis, and matrix detachment-induced cell death (anoikis). In addition, we describe an orthotopic model of metastatic breast cancer that utilizes mCherry-fluorescently-labeled human breast cancer cells. This model captures the entire metastatic cascade from the mammary gland to the lung and mimics key features of the human disease. These breast-cancer models can be readily adapted to other tumor types. Overall, we provide a stepwise, translationally-relevant approach to study metabolic priming in the context of cancer.

摘要

我们已经开发出一种针对癌症的新型治疗模式(“代谢预激”),即限制必需氨基酸甲硫氨酸可激活多种细胞应激反应途径,这些途径可被选择性靶向,以增强甲硫氨酸限制的治疗效果。代谢预激的一个例子是甲硫氨酸限制与促凋亡的肿瘤坏死因子相关凋亡诱导配体受体-2(TRAIL-R2)激动剂联合使用。在乳腺癌的细胞和小鼠模型中,甲硫氨酸限制可选择性地增强转化乳腺上皮细胞表面TRAIL-R2的表达,并使它们对TRAIL-R2激动剂诱导的细胞死亡更敏感。本方法综述聚焦于乳腺癌的临床前模型,以研究通过甲硫氨酸限制进行的代谢预激。详细介绍了多种基于细胞的方法,以测量细胞活力、细胞存活、半胱天冬酶活性、凋亡以及基质脱离诱导的细胞死亡(失巢凋亡)。此外,我们描述了一种转移性乳腺癌的原位模型,该模型利用了mCherry荧光标记的人乳腺癌细胞。该模型捕捉了从乳腺到肺的整个转移级联过程,并模拟了人类疾病的关键特征。这些乳腺癌模型可很容易地应用于其他肿瘤类型。总体而言,我们提供了一种逐步的、与转化相关的方法,用于在癌症背景下研究代谢预激。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c70/6571148/c4fcf877e967/nihms-1027966-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c70/6571148/8f9fb9a61385/nihms-1027966-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c70/6571148/26baa75bd079/nihms-1027966-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c70/6571148/c4fcf877e967/nihms-1027966-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c70/6571148/8f9fb9a61385/nihms-1027966-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c70/6571148/26baa75bd079/nihms-1027966-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c70/6571148/c4fcf877e967/nihms-1027966-f0003.jpg

相似文献

1
Preclinical Breast Cancer Models to Investigate Metabolic Priming by Methionine Restriction.用于研究蛋氨酸限制引发代谢的临床前乳腺癌模型
Methods Mol Biol. 2019;1866:61-73. doi: 10.1007/978-1-4939-8796-2_6.
2
Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression.甲硫氨酸剥夺通过增强TRAIL受体2的表达在三阴性乳腺癌细胞中诱导出一种可靶向的脆弱性。
Clin Cancer Res. 2015 Jun 15;21(12):2780-91. doi: 10.1158/1078-0432.CCR-14-2792. Epub 2015 Feb 27.
3
Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer.靶向三阴性乳腺癌模型中 TRAIL 受体 2 增强转移抑制。
Clin Cancer Res. 2011 Aug 1;17(15):5005-15. doi: 10.1158/1078-0432.CCR-11-0099. Epub 2011 Jun 8.
4
Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.二甲双胍通过抑制X连锁凋亡抑制蛋白(XIAP)的表达,使三阴性乳腺癌对促凋亡的肿瘤坏死因子相关凋亡诱导配体(TRAIL)受体激动剂敏感。
Breast Cancer Res Treat. 2017 Jun;163(3):435-447. doi: 10.1007/s10549-017-4201-0. Epub 2017 Mar 21.
5
Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression.实验性非酒精性脂肪性肝炎中的细胞凋亡与p53激活及肿瘤坏死因子相关凋亡诱导配体(TRAIL)受体表达有关。
J Gastroenterol Hepatol. 2009 Mar;24(3):443-52. doi: 10.1111/j.1440-1746.2009.05785.x. Epub 2008 Feb 15.
6
Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation.组蛋白赖氨酸 N-甲基转移酶 2 的抑制作用通过活性氧介导的激活转录因子 4-C/EBP 同源蛋白-死亡受体 5 途径的激活,使乳腺癌细胞对肿瘤坏死因子相关凋亡诱导配体敏感。
Mol Carcinog. 2018 Nov;57(11):1492-1506. doi: 10.1002/mc.22872. Epub 2018 Jul 19.
7
Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model.口服重组蛋氨酸酶与激动剂替加曲妥珠单抗联合应用可增加 TRAIL 受体-2 的表达,从而在原位小鼠模型中消退胰腺癌。
Cancer Lett. 2020 Nov 1;492:174-184. doi: 10.1016/j.canlet.2020.07.034. Epub 2020 Jul 31.
8
Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.阿司匹林通过降低生存素水平使癌细胞对TRAIL诱导的凋亡敏感。
Clin Cancer Res. 2008 May 15;14(10):3168-76. doi: 10.1158/1078-0432.CCR-07-4362.
9
TRAIL enhances quinacrine-mediated apoptosis in breast cancer cells through induction of autophagy via modulation of p21 and DR5 interactions.TRAIL 通过调节 p21 和 DR5 的相互作用诱导自噬增强了奎纳克林介导的乳腺癌细胞凋亡。
Cell Oncol (Dordr). 2017 Dec;40(6):593-607. doi: 10.1007/s13402-017-0347-3. Epub 2017 Sep 21.
10
SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells.SAHA/TRAIL 联合诱导 MDA-MB231 和 MCF-7 乳腺癌细胞脱落和凋亡。
Biochimie. 2012 Feb;94(2):287-99. doi: 10.1016/j.biochi.2011.06.031. Epub 2011 Jul 31.

引用本文的文献

1
Depression promotes breast cancer progression by regulating amino acid neurotransmitter metabolism and gut microbial disturbance.抑郁通过调节氨基酸神经递质代谢和肠道微生物紊乱促进乳腺癌进展。
Clin Transl Oncol. 2024 Jun;26(6):1407-1418. doi: 10.1007/s12094-023-03367-3. Epub 2024 Jan 9.
2
Artificial Diets with Selective Restriction of Amino Acids and Very Low Levels of Lipids Induce Anticancer Activity in Mice with Metastatic Triple-Negative Breast Cancer.对氨基酸进行选择性限制且脂质水平极低的人工饮食可诱导转移性三阴性乳腺癌小鼠产生抗癌活性。
Cancers (Basel). 2023 Feb 28;15(5):1540. doi: 10.3390/cancers15051540.
3
Stemness of Normal and Cancer Cells: The Influence of Methionine Needs and SIRT1/PGC-1α/PPAR-α Players.正常和癌细胞的干性:蛋氨酸需求和 SIRT1/PGC-1α/PPAR-α 调控因子的影响。
Cells. 2022 Nov 15;11(22):3607. doi: 10.3390/cells11223607.
4
Lysine oxidase exposes a dependency on the thioredoxin antioxidant pathway in triple-negative breast cancer cells.赖氨氧化酶揭示了三阴性乳腺癌细胞对硫氧还蛋白抗氧化途径的依赖性。
Breast Cancer Res Treat. 2020 Oct;183(3):549-564. doi: 10.1007/s10549-020-05801-4. Epub 2020 Jul 21.

本文引用的文献

1
NSG Mice Provide a Better Spontaneous Model of Breast Cancer Metastasis than Athymic (Nude) Mice.与无胸腺(裸)小鼠相比,NSG小鼠能提供更好的乳腺癌转移自发模型。
PLoS One. 2016 Sep 23;11(9):e0163521. doi: 10.1371/journal.pone.0163521. eCollection 2016.
2
Histone Methylation Dynamics and Gene Regulation Occur through the Sensing of One-Carbon Metabolism.组蛋白甲基化动力学和基因调控通过一碳代谢感知发生。
Cell Metab. 2015 Nov 3;22(5):861-73. doi: 10.1016/j.cmet.2015.08.024. Epub 2015 Sep 24.
3
Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression.甲硫氨酸剥夺通过增强TRAIL受体2的表达在三阴性乳腺癌细胞中诱导出一种可靶向的脆弱性。
Clin Cancer Res. 2015 Jun 15;21(12):2780-91. doi: 10.1158/1078-0432.CCR-14-2792. Epub 2015 Feb 27.
4
NanoFlares for the detection, isolation, and culture of live tumor cells from human blood.用于从人血液中检测、分离和培养活肿瘤细胞的纳米荧光探针。
Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17104-9. doi: 10.1073/pnas.1418637111. Epub 2014 Nov 17.
5
Apoptosis initiation through the cell-extrinsic pathway.通过细胞外源性途径启动细胞凋亡。
Methods Enzymol. 2014;544:99-128. doi: 10.1016/B978-0-12-417158-9.00005-4.
6
αB-crystallin: a novel regulator of breast cancer metastasis to the brain.αB-晶状体蛋白:一种调控乳腺癌脑转移的新型分子。
Clin Cancer Res. 2014 Jan 1;20(1):56-67. doi: 10.1158/1078-0432.CCR-13-1255. Epub 2013 Oct 16.
7
Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer.靶向三阴性乳腺癌模型中 TRAIL 受体 2 增强转移抑制。
Clin Cancer Res. 2011 Aug 1;17(15):5005-15. doi: 10.1158/1078-0432.CCR-11-0099. Epub 2011 Jun 8.
8
A first-in-human study of conatumumab in adult patients with advanced solid tumors.一项在成人晚期实体瘤患者中开展的 conatumumab 的首次人体研究。
Clin Cancer Res. 2010 Dec 1;16(23):5883-91. doi: 10.1158/1078-0432.CCR-10-0631. Epub 2010 Oct 14.
9
Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies.综述:基底样乳腺癌:从分子特征到靶向治疗
Mol Endocrinol. 2011 Feb;25(2):199-211. doi: 10.1210/me.2010-0164. Epub 2010 Sep 22.
10
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.一项在晚期癌症患者中进行的重组人 Apo2L/TRAIL(一种双重促凋亡受体激动剂)的 I 期剂量递增研究。
J Clin Oncol. 2010 Jun 10;28(17):2839-46. doi: 10.1200/JCO.2009.25.1991. Epub 2010 May 10.